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Abstract
Organ transplantation presents a low but extant risk of allograft transmission of blood-
borne viruses (BBV) including human immunodeficiency virus (HIV), hepatitis B virus
(HBV), and hepatitis C virus (HCV). Other infections temporarily present in blood are
also transmissible from donor to recipient, such as cytomegalovirus (CMV), polyoma‐
virus (BK), Epstein-Barr virus (EBV), and others, where the donor has acute infection at
the time of donation. Decisions about accepting organs for transplantation involve a
trade-off  between the acquisition of  good-quality organs,  which can confer  longer
survival time for the recipient, but at the risk of dying from waiting too long from the
underlying condition,  versus accepting an organ of  less  quality,  but  at  the risk of
potentially acquiring a donor-derived infection (DDI), unless such infection can be ruled
out in the donated organ. In this chapter, we describe the different factors contribu‐
ting to the overall risk of acquiring a BBV infection through the allograft, mechanisms
for assessing risk of the donor and the different strategies available to minimize or
mitigate the risk. The process is one of risk assessments and risk ameliorations through
optimum  laboratory  and  clinical  assessment  processes,  so  that  transplantation
professionals can balance the overall risk against the life-saving and life-enhancing
benefits of organ transplantation.
Keywords: blood-borne virus infection through transplantation, donor-derived infec‐
tions, risk assessment, risk management, risk mitigation
1. Introduction
Organ transplantation currently provides definitive therapy for individuals with end-organ
failure. Despite the enormous therapeutic advances in this area, donor-derived infections (DDI)
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in the recipient from the donated organ, although rare, have been associated with significant
morbidity and mortality [1,2]. These unexpected DDI are often with blood-borne viruses (BBV),
including  hepatitis  B  virus  (HBV),  hepatitis  C  virus  (HCV),  and less  frequently  human
immunodeficiency virus (HIV) [3–5]. There are few data available to ascertain the risk of infection
in organ transplantation for known and emerging pathogens, as most information comes from
events of transmission, which are rare and not always well characterized, with few countries
having well-established post-transplant surveillance systems with universal recipient assess‐
ment [6].
Due to the scarcity of donor organs, the safety paradigm in solid organ transplantation (SOT)
should be based on a risk-benefit trade-off and the decision-making strategy for organ
allocation be based on risk management. In this context, it is important to consider that most
often the benefits of transplanting the organ outweigh the risk of DDI. Therefore, care should
be taken to find the appropriate balance between minimizing the risk of transmission and
organ wastage or recipient illness progression [7].
This chapter describes the different factors contributing to the overall risk of acquiring a BBV
infection through the allograft, the risk assessment of the donor, and the different strategies
available to minimize or mitigate the risk.
2. Donor assessment
Donor assessment often uses a questionnaire based on review of medical and social history to
identify donor risks, including those associated with infection with blood-borne pathogens.
In Australia, a standard questionnaire is available nationwide to streamline the assessment
criteria [8]. The organ donor coordinator must review all potential donor’s available medical
records to identify evidence of an infectious disease or documentation of established risk
behaviors associated with BBV infection. The information should be obtained from a next of
kin and/or other person who has an established relationship with the donor (e.g. the donor’s
general practitioner). Attention to travel history is critical to identify donors at risk of endemic
infections [9,10].
• Men who have had sex with another man in the preceding 5 years.
• Intravenous, intramuscular, or subcutaneous injection of drugs in the preceding 5 years.
• Incarceration in the previous 12 months.
• Persons who have had sex in the preceding 12 months with any of the above persons or a person known or suspected
to have HIV, HCV, or HBV infection.
• Persons who have engaged in sex in exchange for money or drugs in the preceding 5 years.
• Exposure in preceding 12 months through percutaneous inoculation or open wound.
• Nonsterile tattooing, piercings in the past 12 months.
• Unexplained fever/weight loss/LAD/cough.
• Cocaine snorting.
• Physical concern.
Table 1. Donors with identified risk factors.
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Careful physical assessment of the donor’s body is conducted by both the organ procurement
team and the procuring surgeon. The examination also searches for evidence of underlying
disease, such as cirrhosis or other surface manifestations of infections, malignancies or of recent
drug use [11]. In the acute donation situation, the appropriate person is not always available
to question regarding the donor’s risk, and manifestations of BBV can be minimal or non-
existent. Thus, optimal donor screening testing is of paramount importance.
3. Prevalence of infection
The prevalence of BBV infection on a given population is particularly important as donor
history may fail to uncover donor risk factors and, especially in the case of HBV or HCV, the
rate of prevalent disease remains relatively high in 2016 in many countries, even in donors
without identified risks. BBV potentially transmitted from donor organ to recipient are
prevalent at 2% of the Australian population (Table 2) [12], whereas cytomegalovirus (CMV),
Epstein–Barr virus (EBV), and polyomavirus (BK) virus are far more common, with prevalence
rates of 50–70%, 95% [13], and ∼60% [14], respectively.
Virus estimated Infected
population 
Prevalence 
rate (%) 
Prevalence rate
in high-risk population (%)
HIV 25,700 0.10 2.8
HBV 218,000 0.87 50
HCV 233,525 0.93 50
Total 468,525 1.9 80*
* Some individuals are infected with both HCV and HBV.
Table 2. Prevalence of BBV (HIV-1, HBV, and HCV) in the Australian population.
The prevalence of BBV among potential increased-risk organ donors in our laboratory in the
Serology and Virology Division (SAVID), providing testing services to the NSW Organ and
Tissue Donation Service was 50% for HBV, 10% for HCV, and 0.1% for HIV-1 [15]. In the United
States, the prevalence of HIV and HCV in average-risk donors was reported to be 0.10 and
3.45%, respectively, whereas the prevalence of HIV and HCV among increased risk donors
(IRDs) was 0.50 and 18.20%, respectively [16]. Viruses endemic to certain geographical areas
or population groups including human T-cell lymphotropic virus 1 (HTLV-1) in the Australian
Aboriginal population and HBV in Mediterranean and Asian Countries may be one reason for
unexpected positive screening results of average-risk donors or donors without apparent risk
factors [17]. The WHO publishes updated prevalence figures of BBV worldwide, which could
assist in ascertaining the probability of BBV latent infections [18] and hence background risk
of donor infection.
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4. Serology/nucleic acid testing results
Donors are routinely screened to identify viral or bacterial infection using serology and nucleic
acid testing (NAT) assays. NAT assays detect the presence of specific viral or bacterial
RNA/DNA in a patient’s blood. The latter is a marker of infectivity of the organ donor when
compared with antibody tests, which show previous infection without distinguishing current
infection. All BBV serological tests have a ‘window period’ (WP), which is a time after infection
during which the antibody response cannot be detected by the usual testing methods
(Figure 1). The serological WP varies with the sensitivity of the assay, but generally are 17–22
days for HIV, 38–60 days for HBV, and 70 days for HCV.
Figure 1. Events taking place after viral exposure.
NAT assays significantly reduce the WP between infection and detection compared with
serological testing (6–7 days for HIV, 30–40 days for HBV, and 4–6 days for HCV) (Figure 2).
Thus, NAT assays also have WP when they are negative following acute infection, therefore
a negative NAT assay result does not completely eliminate the possibility of recent infection.
In practice, the risk of infection from screened donors has been extremely low, but no screening
test that is performed on a donor is entirely capable of reducing risk of transmission to nil,
although all efforts are taken to reduce risk of BBV transmission and effectively resulting in
extremely low risk.
All potential organ donors (living or deceased) should be tested for antibodies to HIV (anti-
HIV 1/2 antigen/antibody combo assay), HCV and HBV. Donors should also be tested for HIV,
HCV, and HBV RNA/DNA, whereas increased-risk organ donors should be tested by NAT
for HIV, HCV, and HBV prospectively (Table 3).
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Figure 2. Differences in window periods for serology and NAT for HIV, HCV, and HBV (Data from SAVID).
Serology: NAT:
• Anti-HIV-1/2 • HIV-1 RNA
• Anti-HCV • HCV RNA
• Anti-HTLV-I/II • HBV DNA
• HBsAg • Prospective in increased risk donors
• Anti-HBc • Retrospective in average-risk donors
• Anti-HBs
• Anti-EBV
• Anti-CMV
• Syphilis antibody (TPHA )
Table 3. Mandatory testing for prospective organ donors in Australia.
The WP of an assay has important implications for the risk assessment of a particular donor.
The definition of IRD as per the Transplantation Society of Australia and New Zealand
guidelines [11] is “where there is concern regarding the donor’s risk behavior and it cannot be
reliably determined or the behavior may have occurred within the last 2 months”. These 2
months cover the NAT WPs for HIV, HCV, and HBV (Figure 2).
The arrival of fully automated platforms for triple viral NAT currently in 2016 in Australia by
at least two manufacturers opens the possibility of 24-hour access to HBV, HCV, and HIV NAT
testing. New technologies, such as the Cobas 6800 system [19] from Roche Molecular Systems
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and the Panther system [20] from Hologic, are now available with shorter turnaround time
(TAT = 3.5 hours), and the possibility of confirmatory testing of initially positive results.
5. Conduct of donor testing
If the specimen sample used for testing has unusual characteristics, such as where donors have
had massive blood and/or blood product transfusion, it is essential to indicate to the testing
laboratory and the transplanting team the underlying condition of the donor. If the donor has
received greater than 50% of blood volume in blood product transfusion, the sample is
unsuitable for serology and NAT testing due to dilution of native antibodies by transfused
fluids [21]. A pre-transfusion sample should be provided to the laboratory. If this is not
possible, NAT-enhanced sensitivity may reduce the frequency of false-negative test results
when donor specimens are haemodiluted.
There are significant concerns that the use of assays with higher sensitivity for pathogen
detection—such as NAT assays—will result in net organ loss. This is because the majority of
positive tests in low-prevalence populations will be false positives [22], and time constrains
do not allow confirmatory testing with certain testing platforms. The NAT laboratory at
SAVID, Prince of Wales Hospital in Sydney, Australia, has developed screening algorithms
using three NAT assays run in parallel for prospective screening of IRD to maximize organ
availability by effectively eliminating false-positive results (FPR) [15]. The availability of a 24-
hour NAT screening service for organ donors provided diagnosis within 8 hours and enabled
the use of organs from donors with positive serology but negative NAT results or donors with
false-positive serology results. This algorithm allowed us to perform real-time discrimination
of initially reactive results and the use of 35 IRD, which resulted in transplantation of 102
additional organs with safer expansion of the donor pool.
Positive serology or NAT results should be interpreted consistent with current guidelines
[10,16] by the accepting teams in consultation with an Infectious Disease Physician.
6. Risk of transmission
The risk of acquisition of a BBV through organ transplantation is related to the efficiency of
virus transmission and replication after contact with blood and tissues. Not all BBV are
transmitted in the same way, and the result may be related to the type and size of the inoculum,
the titre of virus and the immunization status of the recipient. Most of the well-documented
transmissions are from blood transfusions but this may correlate with similar level of infec‐
tivity from donated organs. In humans, HBV transmission has been reported to be from blood
donors in the WP or from donors with occult hepatitis B (OBI) with HBV viral loads of >20 IU/
ml [23], whereas donors with an anti-HBs titre of >100 seem to have a protective role to prevent
de novo HBV infection [24]. In terms of HIV, a pre-seroconversion donation with a viral load
of ≤150 copies of RNA/ml went undetected and resulted in an HIV transmission [25]. Finally,
HCV-infected recipients have been reported from donors with a viral load of as low as 182 cp/
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ml and even from a donor with undetectable levels of RNA in the transcription-mediated
amplification (TMA) assay (limit of detection (LOD) = 9.6 IU/ml)) [26].
In a report by the Canadian Society for Transplantation and Canadian National Transplant
Research Program [27], the residual risk to acquire a HIV or HCV infection from transplanted
organs of IRD after screening with serology and NAT was calculated (Table 4). The group
concluded that these donors should screened by serological testing in conjunction with NAT
testing for HCV and HIV and hepatitis B surface antigen (HBsAg) or NAT for HBV.
Virus  Risk of WP
infection for NAT
and ELISA per 10,000
Risk of WP
infection for NAT and ELISA
expressed as ratio
HIV 0.71 1:14,923
HCV 3.79 1:2,637
Table 4. Risk per 10,000 donors of an HIV or HCV infection occurring during the WP, by enzyme-linked
immunosorbent assay (ELISA) and NAT. Assumes a WP of 21 days for ELISA and 7 days for NAT.
7. Organ-specific risks
HBV- and HCV-infected livers produce universally infected HBV- or HCV-naïve recipients,
with outcomes determined by factors, such as the viral genotype, the presence or absence of
previous immunity and the response to antiviral therapy. On the other hand, a HCV- or HBV-
infected donor may be able to donate other organs rather than the liver. As both HBV and HCV
can be transmitted via organ donation, especially through liver grafts, a thorough approach is
needed for successful management of the recipient, and an emphasis on aggressive immuni‐
zation and risk mitigation of transplant candidates prior to transplant should be pursued.
Allografts from HBV-infected donors should preferentially be given to recipients who are
HBsAg positive, hepatitis B core antibody (anti-HBc) positive, or hepatitis B surface antibody
(HBsAb) positive [28]. Transmission of de novo HBV infection to liver grafts recipients from
anti-HBc–positive donors has been detected since 1992; however, further studies demonstrated
that non-liver allografts from these donors can be safely used [29,30]. Several studies have
clearly shown that non-liver organs and tissues from donors who are anti-HBc positive and
HBsAg negative can be used with negligible risk, especially if the recipient is protected through
vaccination or prior exposure to HBV [31,32].
A different scenario is that of donors with OBI, characterized by persistence of HBV DNA in
the liver tissue (and in some cases also in serum) of HBsAg-negative individuals [33], therefore
exhibiting undetectable HBsAg in serum and low-level HBV DNA (<200 IU/ml). In HBV, low-
prevalence countries, the prevalence of OBI is low (0.1–2.4%) [34], whereas in HBV, high-
prevalence countries, the prevalence can range from 7.5 to 16% [35,36].
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The molecular bases of OBI appear to be related to the long-lasting persistence in the nuclei of
the hepatocytes of the HBV cccDNA, an intermediate form of the virus life cycle that serves as
a template for gene transcription [37,38]. The risk of OBI being associated with anti-HBc
seropositivity has been demonstrated [39,40], and one of the best sentinel markers for OBI is
a positive anti-HBc serology result [41]. Long-standing abnormal results of liver function tests
of unknown aetiology in the absence of HBV serological markers and serum HBV DNA may
also indicate the presence of HBV DNA in the liver and peripheral blood mononuclear cells
[42]. Donors with OBI may transmit HBV infection, especially in orthotopic liver transplanta‐
tion (OLT), because the hepatocytes are the reservoir of the viral cccDNA. These recipients
may develop de novo hepatitis B, particularly when they are HBV naïve [43,44]. Prevention
measures include anti-HBV prophylaxis, based on anti-HBs immunoglobulin alone or in
combination with lamivudine. These measures, however, cannot completely eliminate HBV
transmission because there have been documented reports on the development of OBI in
recipients who received an organ from an OBI carrier [44], exhibiting the same viral genomes
(including HBV cccDNA) in the transplanted liver.
As already mentioned, HBV-infected donors can be safely used for potential HBV-infected
recipients [28] with the use of post-transplantation prophylaxis (hepatitis B immune globulin
(HBIg) and nucleoside/nucleotide polymerase inhibitors, such as lamivudine in combination
with adefovir, entecavir, or tenofovir) [45–47]. It has also been reported that a titre of HBsAb
greater than 100 in the donor has a protective effect [48]. Recipient sero-protection through
prior exposure or vaccination is a highly effective way to prevent transmission of HBV through
organ transplantation [49]. As some potential organ recipients do not respond well to vacci‐
nation and remain unprotected, a priority area is to devise new ways to enhance vaccination
responses.
HCV-positive donor organs can also be used in HCV-positive recipients with minimal impact
on clinical outcomes [50,51]. Clinical studies have shown that there is no significant difference
in survival in HCV-positive recipients who receive either HCV-positive or HCV-negative
livers or kidneys [51–55]. Therefore, there needs to be education to enhance uptake of HCV-
positive organs in HCV-positive recipients. As first-generation direct acting antivirals (DAAs)
offer a significant therapeutic improvement when compared with previous therapies, partic‐
ularly for patients with HCV genotype-1 infection, this may lead to the use of more HCV-
infected organ donors for HCV-infected recipients treated with this highly effective post-
transplant prophylaxis [56,57].
8. Use of IRDs
In the United States alone, almost 10,000 individuals die annually while awaiting organ
transplantation [58], whereas in Australia, there are almost 3000 individuals in the waiting list.
Due to organ scarcity, attempts at expanding the pool of potential donors are necessary, and
the criteria for donation are under continuous scrutiny. Recent campaigns globally from organ
procurement agencies to expand the donor pool have resulted in use of organs from IRD, who
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are at greater risk of infection with BBV, including HBV, HCV, and HIV. The use of NAT to
screen such IRD has been associated with increased utilization of these organs [10,11,16,27].
The key to using these IRD is to maximize the measures to identify risk factors; particularly
ensuring that infectious diseases are not transmitted from donor to recipient in the allograft.
A successful strategy to mitigate the overall risk has been to match the allograft to the most
appropriate recipient by improved selection and monitoring. In such scenarios, additional
consent and recipient screening at regular intervals during the first year after transplant should
be performed [10,11,16,27].
We documented in one study that with the use of prospective NAT, 102 additional organs
from IRD were used in Australia. These organs would otherwise have been discarded or used
with restrictions [15]. This represents 18.8% of all organs transplanted during the study period.
Furthermore, the utilization of parallel NAT assays combined with mathematical modeling
enabled us to estimate the probability that the combination of results were predictive of true-
positive results. Thus, we piloted a methodology for effectively minimizing FPR. This resulted
in higher confidence in the NAT results and minimizing the loss of organs secondary to FPR
to negligible.
In a Canadian study of 3746 transplants using deceased liver donors [59], it was concluded
that over the last decade, there was an increase in the use of older donors and donation after
cardiac death (DCD) organs, but recipient survival was not compromised. In Australia, IRDs
are routinely used, and this strategy has substantially contributed to an increased use of organs
[15]. Furthermore, the acceptance of these organs by the transplantation community has been
increased over the years, and from 2013 onwards, the same number of organs was retrieved
from IRD and from average-risk donors (Figure 3).
Figure 3. Number of organs retrieved from increased-risk donors vs average-risk donors over the years (data from SA‐
VID).
Final decisions in individual cases about using organs of IRD must acknowledge the recom‐
mendations from national and international guidelines, the risk-benefit trade-off in the context
of the gravity of recipient’s prognosis without transplantation, consideration of all clinical and
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laboratory assessment parameters and a fully informed consent and risk acceptance by the
recipient.
9. Scoring the risk
Decision aids are increasingly being developed to support transplantation teams in making
difficult treatment decisions involving trade-offs between provision of a good quality organ
with longer survival but longer wait pre-transplant versus accepting an organ of less quality
with earlier transplantation but higher risk of shorter survival post-transplantation or post-
transplant infections. Furthermore, transplant providers who are helping patients to make
treatment decisions may find it difficult to communicate the risks associated with each option
in a clear, understandable fashion, particularly for IRD organs, given the complexities of risk
assessment.
Scoring systems to indicate recipient’s gravity include the Model for End-Stage Liver Disease
(MELD) score, which is a scoring system for assessing the severity of chronic liver disease. It
was found to be useful in determining prognosis and prioritizing for receipt of a liver trans‐
plant [60]. The score was developed by the Organ Procurement and Transplantation network
(OPTN)/United Network for Organ Sharing (UNOS) and implemented in February 2002.
MELD uses the patient’s values for serum bilirubin, serum creatinine, and the international
normalized ratio for prothrombin time (INR) to predict survival. It is calculated according to
formula [61]. On the other hand, the donor risk index (DRI) by Feng et al. [62] using Organ
Procurement and Transplantation Network (OPTN) data was developed as a continuous
scoring system that includes donor and transplant parameters that significantly influence
outcomes after liver transplantation (LTx). The author undertook a multivariate analysis of a
large cohort (20,023 transplants) from the Scientific Registry of Transplant Recipients database.
The parameters used were the donor’s age, race, height, and cause of death (COD); the split
liver donation status; the donation after cardiac death (DCD) status; the type of allocation
(local, regional, or national); and the cold ischaemia time.
The DRI was validated in a study conducted by the Eurotransplant region, which aimed to
identify its potential use [63]. The study was a database analysis of all 5939 liver transplants
involving deceased donors and adult recipients from January 1, 2003, to December 31, 2007,
in the Eurotransplant region. Follow-up data were available for 5723 patients with a median
follow-up of 2.5 years. The mean DRI was remarkably higher in the Eurotransplant region
versus OPTN (1.71 versus 1.45). The results demonstrated that Kaplan-Meier curves per DRI
category showed a significant correlation between the DRI and outcomes (p < 0.001). A
multivariate analysis demonstrated that the DRI was the most significant factor influencing
outcomes (p < 0.001). Among all donor, transplant, and recipient variables, the DRI was the
strongest predictor of outcomes.
In another study [64], it was investigated the impact of the DRI on the outcome of HCV-infected
patients undergoing LTx, where the median DRI was 1.3 (range, 0.77–4.27). Increasing DRI
was associated with a statistically significant increase in the relative risk (RR) of graft failure
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and patient death for both HCV (+) and HCV (−) recipients. Finally, Rosemberg et al. [65] using
a prospectively collected infection data set, matched liver transplant recipients (and the
respective allograft DRI scores) with their specific post-transplant infectious complications.
All transplant recipients were organized by DRI score and divided into groups with low-DRI
and high-DRI scores. Three hundred and seventy-eight liver transplants were identified, with
189 recipients each in the low-DRI and high-DRI groups. The mean MELD scores were 26.25–
0.53 and 24.76–0.55, respectively (p = 0.052), and the mean number of infectious complications
per patient were 1.60–0.19 and 1.94–0.24, respectively (p = 0.26). Logistic regression showed
only length of hospital stay and a history of vascular disease as being associated independently
with infection, with a trend toward significance for MELD score (p = 0.13). The study concluded
that although DRI score predicts liver graft survival, infectious complications depended more
heavily on recipient factors.
Even though organs from donors with high DRI score correlate with poorer post-transplant
survival, the overall contribution of high-DRI grafts to the donor pool and the resultant
reduction in wait list mortality make them cost-effective [66].
10. Clinical guidelines
Deciding how to allocate organs for transplantation is a very complex process and raises a
number of clinical and ethical issues. Up-to-date guidelines provide an overarching framework
to facilitate the decision-making process in clinical robust ways based on previous evidence.
In general, transplantation guidelines follow many of the recommendations in place for the
selection and microbiological testing of blood donors. However, as in organ donation and
transplantation, the logistics are greatly influenced by the need to retain organ viability, the
testing of potential donors will be conducted under severe time constraints. In these situations,
the testing that needs to be carried out, and the general principles for balancing the risks and
benefits are unique to this field.
Some of the most important transplantation guidelines published recently are as follows:
• PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C
Virus Transmission Through Organ Transplantation was published in the United States in
August 2013 [16]. The aim of the guide was to improve organ transplant recipient outcomes
by reducing the risk of HIV, HBV, and HCV transmission. The guide is truly comprehensive
and based on systematic reviews. It is extremely detailed and specialized and not very
practical for the daily use of transplantation professionals.
• Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO) published the
Guidance on the Microbiological Safety of Human Organs, Tissues and Cells Used for Transplan‐
tation in February 2011 in the United Kingdom [67]. The guidance was written by a working
group after extensive consultation and is extremely clear, accurate, and user friendly.
However, as professionals involved in transplantation need to take real-time decisions that
could be life saving for patients, most of the information given in the guidance could have
been summarized and presented on tables to facilitate the information to readers.
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• The Council of Europe in 2013 published the 5th edition of the Guide to the Quality and Safety
of Organs for Transplantation [68]. This guideline collates updated information to provide
professionals in transplantation with a useful overview of the most recent advancements in
the field. The guide has a very comprehensive section on risk of transmission of infectious
diseases. However, as pointed out before, the information is too comprehensive and should
have been summarized.
• Transplantation Society of Australia and New Zealand (TSANZ) published version 1.4 of
the guideline Organ Transplantation from Deceased Donors: Consensus Statement on Eligibility
Criteria and Allocation Protocols in April 2015 [11]. The guide has only one section related to
transmission of infectious agents from donor to recipient with data from HCV and HBV
infection risks alone. The information is insufficient as many other real-life situations are
not contemplated. Within Australia, the NSW Ministry of Health published the guide Organ
Donation and Transplantation—Managing Risks of Transmission of HIV, HCV and HBV in 2013
[10]. This is a very useful guide for transplantation professionals.
Ideally, guidelines for transplantation should be comprehensive but presented in a concise
manner to facilitate its use to readers, as shown in Table 5 [69].
Donor
status 
Advice  References 
Antibody to
HIV (+)
Exclude from organ donation [11,67]
Antibody to
HCV (+)
Exclude from organ donation for HCV (−) recipients If used, usually reserve
organ for recipient HCV (+) or severely ill recipient. HCV RNA testing should be
done and allocated to a donor with a higher HCV viral load
[11,67]
Hepatitis B surface
antigen HBsAg (+)
Exclude from organ donation. Use in life-threatening situations with recipient
antiviral prophylaxis against HBV
[11,67]
Hepatitis B core
antibody IgG (anti-
HBc) (+)
Indicates past HBV infection. Organs from anti-HBc (+) of anti-HBs (−) may
still be infectious. High risk for transmission with liver donation—generally used
with intensive prophylaxis. Non-hepatic organs—small risk of transmission of
HBV, and generally used for immunized HBsAb (+) recipients
[11,67,70,71]
Hepatitis B surface
antibody Anti-HBs
(+)
Anti-HBs >100 IU/l and anti-HBc (+) donations unlikely to be infectious and
donation is permitted with the potential exception of livers (see above).
HBV DNA NAT should be done and available prior to organ donation HBV DNA
(−) indicates suitability for donation, though does not exclude risk of infection from
liver. Use in vaccinated recipients and with negative NAT testing if donor
vaccination unknown
[11,67,70,71]
Antibody to
CMV (+)
Donation permitted. Post-transplant CMV monitoring and preventive strategy
based on risk to the recipient
[67]
Antibody to
EBV (+)
PCR monitoring of the seronegative or paediatric recipient [67]
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Donor
status 
Advice  References 
RPR (+) Not a contraindication to donation. Recipients receive standard
prophylaxis (benzathine penicillin or ceftriaxone). Ensure administration of
adequate antimicrobial therapy and the patient should be monitored for
serological evidence of syphilis infection
[11,67,70,71]
Antibody to
HTLV I/II (+)
High rate of false-positive results and consistent strategy not available.
Some centers exclude from organ donation or use for life-threatening situations,
with informed consent
[11,67,71]
Antibody to
Toxoplasma IgG (+)
Not a contraindication to donation. Seronegative recipients with a
seropositive donor should receive prophylaxis. Cardiac recipients particularly
prone to transplant-associated toxoplasmosis
[11,67,71]
Viral encephalitis Unknown etiology in donor is a contraindication to transplantation (risk of rabies,
West Nile Virus or other exotic neurotropic infections). HSV or VZV CNS infection
is a contraindication as it may cause systemic infection. HSV encephalitis without
evidence of systemic infection treated with antivirals may be used, and antiviral
prophylaxis should be used for the recipient. Local HSV/VZV infection
treated with adequate antiviral therapy for >7 days organs can be used; if treated
<7 days, recipient should receive antiviral prophylaxis (the serological status of the
recipient must be known)
[67]
Anti-HBs, hepatitis B surface antibody; IgG, immunoglobulin G; RPR, rapid plasma reagin; VZV, Varicella Zoster
virus.
Table 5. Recommendations for organ allocation based on screening data as at 2015 – subject to change with changes in
policy.
This kind of format is how the Scandinavian guidelines have been presented and this could
be a very useful resource for professionals identifying organ donors, transplant co-ordinators
managing the donation process, and transplant physicians responsible for organ allocation
[72].
11. Risk stratification and management
Currently, there are two ways in which organ donors are risk stratified in Australia: donors
are dichotomized as being either at increased risk (IRD) or without identified risk factors for
transmission of infectious diseases. Figure 4 shows the flowchart for BBV testing and risk
stratification in New South Wales (NSW), Australia [10].
In principle, any reactivity in one or more of the mandatory marker assays used for screening
donors renders the donor ineligible. However, in life-preserving situations, it is possible to
waive this exclusion. The risk-benefit trade-off means that using an IRD should only be
considered when the donation is life-preserving. In this situation, the transplant surgeon with
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the informed consent of the potential recipient should balance the risk of infection against the
risk of dying while waiting for another graft. Heart, lung, and liver transplants will almost
always fit within this definition because the clinical situation of the recipient is likely to be
terminal. However, short-term or intermediate support measures can be employed to avoid
the immediate need for transplantation with an organ from an IRD.
Figure 4. Blood-borne virus testing and risk stratification flowchart (from Organ Donation and Transplantation – Man‐
aging Risks of Transmission of HIV, HCV, and HBV). Reproduced with permission from NSW Ministry of Health,
2015.
One strategy when using IRD is matching infection status of donor and recipient. Previous
infection, current infection, or immunization may decrease or remove the risk of infection
following the use of a transplant from a donor who is known to be infected. Thus, it is
appropriate to consider the use of an organ from a donor who is known to be infected, or who
is potentially infected with HCV or HBV or a recipient who is also infected with HCV or HBV
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(i.e. infection match). Another approach involves matching of the immune status of the
recipient to the infection status of the donor. For example, a recipient shown to be immune to
hepatitis B, naturally or by immunization, is unlikely to suffer re-infection from an HBV-
infected donor. In this type of matching, it is essential that the status of the recipient is known
with certainty.
Matching the status will also include an assessment of the likelihood of transmitting viral
genotypes, which may pose an additional hazard to the already infected recipient, such as
using an organ infected with HCV genotype 1 for a non-1 genotype–infected recipient; drug-
resistant variants, and immune escape variants. Infectious Disease specialist support should
be sought to ensure that appropriate testing has been undertaken to inform the risk assessment
and to confirm the recipient’s status.
Risk mitigation measures include the use of prophylaxis with antiviral drugs or antibiotics;
counseling and discussing with the recipient the potential infection risk and the possibility of
disease arising from infection. In addition, a full informed consent and post-transplant
surveillance for infection of the recipient with planned interventions should they become
necessary in the case of infection transmission should be undertaken.
12. Post-transplant surveillance
The final verification of risk estimates for DDI is carried out using post-transplant surveillance
aiming to identify possible donor-derived events and clusters of transmissions. These proce‐
dures require careful post-transplant follow-up, diligent clinicians to suspect and report cases
and reporting systems to accept and inform investigation of potential transmission reports in
a proactive manner. These systems, if universally instituted, could improve investigation of
potential clusters of infection, with enhanced rapid detection and improved advice to clini‐
cians. Furthermore, they can be valuable resources for examination of clinical data to establish
evidence-based guidelines.
Recent biovigilance initiatives in the United States and Europe have occurred with the aim of
developing national surveillance systems for cells, tissues, and organs. In Europe, the Eustite
project [73] initiated in 2008 focused especially on inspection, training, and vigilance for tissue
banks. The project developed special tools and a system for the classification and reporting of
adverse events to all European countries that could be used internationally for biovigilance
and surveillance. Subsequently, the tools developed by the Eustite project were streamlined
by the WHO, resulting in an educational program designed for organs and tissues through
the NOTIFY Project. The vigilance information database collected by the Notify Project is
available on the WHO/CNT Global NOTIFY Library website [74]. The library aims to be a
comprehensive reference of different types of adverse events and reactions identifying their
underlying root causes. The library is regularly maintained and updated and serves as a
communication hub for transplantation institutions with international vigilance and surveil‐
lance data to enhance donor and recipient safety and for greater public transparency in
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transplantation. The project also aims to be a reference of internationally terminology for
biovigilance of organs, tissues, and cells.
The US program monitoring DDI (the UNOS and the Disease Transmission Advisory Com‐
mittee (DTAC)) [75] undertakes data collection and dissemination on pre-transplant and post-
transplant events and examines and classifies potential donor-derived transmission through
transplantation of infection or malignancy. These aim to educate the transplant community
and help change policy and improve processes. The membership includes CDC, FDA,
transplant centers, transplant infectious disease professionals, laboratory testing personnel,
and organ procurement organizations. The OPTN currently requires reporting of donor-
derived events. All potential donor-derived transmission events (PDDTE) reported to OPTN/
UNOS are reviewed by the DTAC, and real-time reports are available for transplantation
professionals.
The ANZDATA [76] registry in Australia and New Zealand is a retrospective reporting system
to evaluate data from donors and recipients. Attempts are recently made for timely data
collection of key events and the creation of a real-time Web-based system utilization, including
historical data for all years and real-time data for the current year grouped by country and
state with interactive reports that can be generated at any point of time.
Most of the established surveillance systems are passive, that is laboratories notify positive
test results to public health regulators. Thus, only recipients tested are notified. This system is
far from ideal as most infections with a BBV do not have symptoms at the time of infection
and an infected recipient may not be tested for some time post-transplant. Furthermore, not
all notifications are followed up, so a recently infected organ recipient may not be detected
even if tested and notified.
Despite the efforts in many countries to gather transplantation data, the main difficulty seems
to lie in the absence of dedicated organ donation and transplantation surveillance registries,
as usually the transplant team reports back to the organ donation agency and the data are not
shared. The transplantation community requires a real-time worldwide surveillance system
to identify possible clusters of infections worldwide. This could be achieved through data
linkage from already established biovigilance programs. An important aspect of biovigilance
systems is to develop data linkages with public health regulators and healthcare providers, so
that the integration of databases can be conducted to strengthen responses to potential BBV
threats worldwide.
13. Conclusions
The development of national policies for risk assessment and definition of acceptable levels of
risk for BBV infection—including specific risk-benefit assessments—is increasing safety,
equity and transparency in organ allocation. All decisions related to virological risk assessment
need to be supported by up-to-date guidelines, optimal diagnostic testing and ongoing
surveillance for DDI post-transplantation. This will continue to result in additional use of
organs and continuous improvement of transplantation outcomes.
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